{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:41:57Z","timestamp":1793263317595,"version":"4.5.0"},"reference-count":10,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Clinical management of congenital hyperinsulinism (CHI) remains a significant challenge due to its complex pathophysiology and the limitations of available therapies. Dasiglucagon, a synthetic glucagon analog, represents a novel approach to managing CHI, particularly in patients where conventional therapies fail. This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI. Despite initial stabilization of glycemic levels, the patient developed necrolytic migratory erythema (NME), a rare dermatological condition associated with hyperglucagonemia, during dasiglucagon therapy. The patient further experienced severe malnutrition, zinc and amino acid deficiencies, and sepsis. Following the discontinuation of dasiglucagon therapy due to these severe side effects, the patient\u2019s skin and nutritional status improved markedly. However, glycemic control required subtotal pancreatectomy. This report underscores the potential of dasiglucagon in CHI management but highlights the importance of close monitoring during prolonged therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>NME, a rare but severe condition, appears to be associated with prolonged continuous subcutaneous dasiglucagon therapy, requiring early recognition and intervention.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Close monitoring is essential during prolonged continuous subcutaneous dasiglucagon therapy to detect potential adverse effects, focusing on dermatological conditions, nutrient deficiencies or signs of infection.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Multidisciplinary care is crucial to manage CHI with dasiglucagon, ensuring a comprehensive approach that addresses both glycemic control and potential side effects.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/edm-25-0006","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T14:27:00Z","timestamp":1745936820000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":3,"title":["Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event"],"prefix":"10.1530","volume":"2025","author":[{"given":"Lucas","family":"Weschle","sequence":"first","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Potratz","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rutsch","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Humberg","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Oesingmann","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pascher","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-569X","authenticated-orcid":true,"given":"Alexander S","family":"Busch","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6127-2580","authenticated-orcid":true,"given":"Katja","family":"Masjosthusmann","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"J Clin Endocrinol Metab","first-page":"In press","article-title":"Dasiglucagon in children with congenital hyperinsulinism up to 1 year of age: results from a randomized clinical trial","author":"De Le\u00f3n DD","year":"2024","unstructured":"De Le\u00f3n DD\n, \nBanerjee I\n, \nKummer S\n, et al\n. Dasiglucagon in children with congenital hyperinsulinism up to 1 year of age: results from a randomized clinical trial. J Clin Endocrinol Metab 2024 [In press] dgae818. (https:\/\/doi.org\/10.1210\/clinem\/dgae818)"},{"key":"bib2","series-title":"Diabetes Care","first-page":"1361","article-title":"Dasiglucagon-a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial","volume":"44","author":"Pieber TR","year":"2021","unstructured":"Pieber TR\n, \nAronson R\n, \nH\u00f6velmann U\n, et al.\n Dasiglucagon-a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial. Diabetes Care 2021 44 1361\u20131367. (https:\/\/doi.org\/10.2337\/dc20-2995)"},{"key":"bib3","series-title":"Eur J Endocrinol","first-page":"531","article-title":"The glucagonoma syndrome and necrolytic migratory erythema: a clinical review","volume":"151","author":"van Beek AP","year":"2004","unstructured":"van Beek AP\n, \nde Haas ERM\n, \nvan Vloten WA\n, et al.\n The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 2004 151 531\u2013537. (https:\/\/doi.org\/10.1530\/eje.0.1510531)"},{"key":"bib4","series-title":"Diabetologia","first-page":"1208","article-title":"Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a phase II, randomised, open-label, two-period crossover trial","volume":"66","author":"Laugesen C","year":"2023","unstructured":"Laugesen C\n, \nRanjan AG\n, \nSchmidt S\n, et al.\n Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a phase II, randomised, open-label, two-period crossover trial. Diabetologia 2023 66 1208\u20131217. (https:\/\/doi.org\/10.1007\/s00125-023-05909-4)"},{"key":"bib5","series-title":"Horm Res","first-page":"59","article-title":"Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon","volume":"70","author":"Mohnike K","year":"2008","unstructured":"Mohnike K\n, \nBlankenstein O\n, \nPfuetzner A\n, et al.\n Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 2008 70 59\u201364. (https:\/\/doi.org\/10.1159\/000129680)"},{"key":"bib6","series-title":"MedGenMed","first-page":"4","article-title":"Etiology and pathogenesis of necrolytic migratory erythema: review of the literature","volume":"6","author":"Tierney EP","year":"2004","unstructured":"Tierney EP\n & \nBadger J\n\n. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed 2004 6 4."},{"key":"bib7","series-title":"N Engl J Med","first-page":"1926","article-title":"Congenital glutamine deficiency with glutamine synthetase mutations","volume":"353","author":"H\u00e4berle J","year":"2005","unstructured":"H\u00e4berle J\n, \nG\u00f6rg B\n, \nRutsch F\n, et al.\n Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med 2005 353 1926\u20131933. (https:\/\/doi.org\/10.1056\/nejmoa050456)"},{"key":"bib8","series-title":"Prog Lipid Res","first-page":"41","article-title":"Nutritional and hormonal factors influencing desaturation of essential fatty acids","volume":"20","author":"Brenner RR","year":"1981","unstructured":"Brenner RR\n\n. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 1981 20 41\u201347. (https:\/\/doi.org\/10.1016\/0163-7827(81)90012-6)"},{"key":"bib9","series-title":"An Bras Dermatol","first-page":"09","article-title":"Paraneoplastic cutaneous manifestations: concepts and updates","volume":"88","author":"Silva JAda","year":"2013","unstructured":"Silva JAda\n, \nMesquita Kd C\n, \nIgreja ACd SM\n, et al.\n Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol 2013 88 09\u201322. (https:\/\/doi.org\/10.1590\/s0365-05962013000100001)"},{"key":"bib10","series-title":"Clin Endocrinol","first-page":"827","article-title":"Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome","volume":"57","author":"Alexander EK","year":"2002","unstructured":"Alexander EK\n, \nRobinson M\n, \nStaniec M\n, et al.\n Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol 2002 57 827\u2013831. (https:\/\/doi.org\/10.1046\/j.1365-2265.2002.01660.x)"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2025\/2\/EDM-25-0006.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2025\/2\/EDM-25-0006.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2025\/2\/EDM-25-0006.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:34Z","timestamp":1784555314000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":10,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/edm-25-0006","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}